NASDAQ:ISO IsoPlexis - ISO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IsoPlexis Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.76 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.76▼$0.7650-Day Range$0.74▼$1.4852-Week Range$0.60▼$5.10VolumeN/AAverage Volume44,584 shsMarket Capitalization$30.28 millionP/E RatioN/ADividend YieldN/APrice Target$1.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media IsoPlexis MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside110.1% Upside$1.60 Price TargetShort InterestHealthy0.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.31) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector429th out of 986 stocksAnalytical Instruments Industry13th out of 28 stocks 3.0 Analyst's Opinion Consensus RatingIsoPlexis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.60, IsoPlexis has a forecasted upside of 110.1% from its current price of $0.76.Amount of Analyst CoverageIsoPlexis has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.74% of the float of IsoPlexis has been sold short.Short Interest Ratio / Days to CoverIsoPlexis has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IsoPlexis has recently decreased by 42.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIsoPlexis does not currently pay a dividend.Dividend GrowthIsoPlexis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISO. Previous Next 1.8 News and Social Media Coverage News SentimentIsoPlexis has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IsoPlexis this week, compared to 1 article on an average week.Social Mentions This WeekMarketBeat has tracked 1 reddit mention for IsoPlexis this week, compared to 0 mentions on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IsoPlexis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of IsoPlexis is held by insiders.Percentage Held by Institutions44.91% of the stock of IsoPlexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for IsoPlexis are expected to grow in the coming year, from ($1.31) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IsoPlexis is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IsoPlexis is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIsoPlexis has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IsoPlexis (NASDAQ:ISO) StockIsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Read More Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address ISO Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comAnalyzing IsoPlexis (ISO) and The CompetitionMarch 23, 2023 | americanbankingnews.comIsoPlexis (ISO) and Its Competitors Head-To-Head AnalysisMarch 23, 2023 | Weiss Ratings (Ad)Banking NightmareDuring and after the Great Financial Crisis of 2008, 485 U.S. banks went under. Here at Weiss Ratings, we warned about 484 — an accuracy rate of 99.8%. Now, we have a new warning. But this time, it's not just about a few hundred banks … it's about nearly every single bank in America …March 21, 2023 | finance.yahoo.comPhenomeX Strengthens Commercial Leadership TeamMarch 21, 2023 | americanbankingnews.comContrasting Harvard Bioscience (NASDAQ:HBIO) and IsoPlexis (NASDAQ:ISO)March 17, 2023 | americanbankingnews.comIsoPlexis (ISO) vs. Its Competitors Head to Head SurveyFebruary 18, 2023 | finance.yahoo.comIsoPlexis Corporation (ISO) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | finance.yahoo.comIsoPlexis Corporation's (NASDAQ:ISO) recent US$6.3m market cap decline means a loss of US$65k for insiders who bought this yearMarch 23, 2023 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. February 4, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates IsoPlexis CorporationJanuary 15, 2023 | finanznachrichten.deIsoPlexis Corporation: Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology CompanyJanuary 12, 2023 | benzinga.comIsoPlexis Granted U.S. Patent Titled 'METHODS OF USING NUCLEOTIDE ANALOGUES'January 12, 2023 | msn.comIsoPlexis expects FY22 revenue to be below consensusJanuary 12, 2023 | finance.yahoo.comIsoPlexis Reports Preliminary Full Year 2022 RevenueJanuary 10, 2023 | msn.comBerkeley Lights' Preliminary 2022 Results Deficient, Analysts Say All Eyes On IsoPlexis ExecutionJanuary 5, 2023 | msn.comMorgan Stanley Maintains Equal-Weight Rating for IsoPlexis: Here's What You Need To KnowDecember 23, 2022 | barrons.comThinking about buying stock in Mullen Automotive, Cleveland-Cliffs, CarMax, IsoPlexis, or Teva Pharmaceutical?December 23, 2022 | markets.businessinsider.comAnalysts Conflicted on These Technology Names: Workday (WDAY) and IsoPlexis (ISO)December 23, 2022 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IsoPlexis Corporation BuyoutDecember 22, 2022 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of IsoPlexis (ISO)December 22, 2022 | marketwatch.comBerkeley Lights Shares Reverse Course, Rise 19% After IsoPlexis TransactionDecember 22, 2022 | markets.businessinsider.comNasdaq Down Over 3%; IsoPlexis Shares Spike HigherDecember 22, 2022 | investorplace.comWhy Is IsoPlexis (ISO) Stock Up 80% Today?December 21, 2022 | marketwatch.comBerkeley Lights to Acquire IsoPlexis in $57.8M Stock DealDecember 21, 2022 | benzinga.comISO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of IsoPlexis Corporation Is Fair to ShareholdersDecember 21, 2022 | marketwatch.comStocks to Watch: IsoPlexis, Lexicon Pharma, Micron Tech, Berkeley LightsNovember 12, 2022 | finance.yahoo.comIsoPlexis Third Quarter 2022 Earnings: Misses ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address ISO Company Calendar Last Earnings3/02/2023Today3/23/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISO CUSIPN/A CIK1615055 Webisoplexis.com Phone203-208-4111FaxN/AEmployees459Year FoundedN/APrice Target and Rating Average Stock Price Forecast$1.60 High Stock Price Forecast$1.70 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+110.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net Margins-632.41% Pretax Margin-632.40% Return on Equity-127.86% Return on Assets-71.41% Debt Debt-to-Equity Ratio1.12 Current Ratio4.06 Quick Ratio2.50 Sales & Book Value Annual Sales$16.76 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.73Miscellaneous Outstanding Shares39,760,000Free Float37,218,000Market Cap$30.28 million OptionableNot Optionable Beta1.32 Key ExecutivesMr. Sean Mackay (Age 40)Co-Founder, CEO, Pres & Director Comp: $635.55kMr. John R. Strahley CPA (Age 55)Chief Financial Officer Comp: $444.11kMr. Rong FanCo-Founder & Chairman of Scientific Advisory BoardMr. Jon ChenVP of Scientific Alliance Technology & Co-FounderMr. Anthony CatalanoSr. VP of OperationsMr. Rajesh T. KhakharVP of Fin. & Principal Accounting OfficerMs. Jing Zhou M.D. (Age 52)Ph.D., Chief Scientific Officer Mr. Richard W. Rew II (Age 54)Sr. VP, Gen. Counsel & Sec. Ms. Verna SiuSr. VP of Sales OperationsMs. Carrie CarterSr. VP of People OperationsMore ExecutivesKey CompetitorsTalis BiomedicalNASDAQ:TLISPrecipioNASDAQ:PRPOAccelerate DiagnosticsNASDAQ:AXDXRapid Micro BiosystemsNASDAQ:RPIDTelesis BioNASDAQ:DNAYView All CompetitorsInsiders & InstitutionsCrystalline Management Inc.Bought 278,125 shares on 3/13/2023Ownership: 0.700%Glenview Capital Management LLCBought 1,970,000 shares on 2/15/2023Ownership: 4.977%Norges BankBought 629,000 shares on 2/15/2023Ownership: 1.589%Morgan StanleyBought 502,473 shares on 2/15/2023Ownership: 1.280%Millennium Management LLCSold 69,798 shares on 2/15/2023Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions ISO Stock - Frequently Asked Questions Should I buy or sell IsoPlexis stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoPlexis in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ISO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISO, but not buy additional shares or sell existing shares. View ISO analyst ratings or view top-rated stocks. What is IsoPlexis' stock price forecast for 2023? 2 Wall Street analysts have issued 12-month price targets for IsoPlexis' shares. Their ISO share price forecasts range from $1.50 to $1.70. On average, they expect the company's stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View analysts price targets for ISO or view top-rated stocks among Wall Street analysts. How have ISO shares performed in 2023? IsoPlexis' stock was trading at $1.55 at the start of the year. Since then, ISO shares have decreased by 50.9% and is now trading at $0.7616. View the best growth stocks for 2023 here. Are investors shorting IsoPlexis? IsoPlexis saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 115,500 shares, a decrease of 42.8% from the February 13th total of 201,800 shares. Based on an average trading volume of 923,200 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the shares of the stock are sold short. View IsoPlexis' Short Interest. When is IsoPlexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our ISO earnings forecast. How were IsoPlexis' earnings last quarter? IsoPlexis Co. (NASDAQ:ISO) released its quarterly earnings results on Thursday, March, 2nd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.45. The business earned $3.36 million during the quarter, compared to the consensus estimate of $5.92 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%. What guidance has IsoPlexis issued on next quarter's earnings? IsoPlexis updated its FY 2022 earnings guidance on Sunday, January, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16.60 million-$16.80 million, compared to the consensus revenue estimate of $19.51 million. When did IsoPlexis IPO? (ISO) raised $125 million in an initial public offering on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share. What is IsoPlexis' stock symbol? IsoPlexis trades on the NASDAQ under the ticker symbol "ISO." Who are IsoPlexis' major shareholders? IsoPlexis' stock is owned by a number of institutional and retail investors. Top institutional investors include Glenview Capital Management LLC (4.98%), Norges Bank (1.59%), Morgan Stanley (1.28%), Crystalline Management Inc. (0.70%), Geode Capital Management LLC (0.39%) and JBF Capital Inc. (0.33%). Insiders that own company stock include John Strahley, Nachum Shamir, Richard W Rew II and Sean Mackay. View institutional ownership trends. How do I buy shares of IsoPlexis? Shares of ISO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IsoPlexis' stock price today? One share of ISO stock can currently be purchased for approximately $0.76. How much money does IsoPlexis make? IsoPlexis (NASDAQ:ISO) has a market capitalization of $30.28 million and generates $16.76 million in revenue each year. The company earns $-106,000,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. How many employees does IsoPlexis have? The company employs 459 workers across the globe. How can I contact IsoPlexis? IsoPlexis' mailing address is 35 NE INDUSTRIAL ROAD, BRANFORD CT, 06405. The official website for the company is isoplexis.com. The company can be reached via phone at 203-208-4111 or via email at investors@isoplexis.com. This page (NASDAQ:ISO) was last updated on 3/23/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.